Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults

J Infect Dis. 1995 Mar;171(3):676-9. doi: 10.1093/infdis/171.3.676.

Abstract

The response to an inactivated hepatitis A vaccine was assessed in 307 persons: 163 Alaska Native children, ages 3-6 years, and 144 Native (84) and non-Native (60) adults. All adults received the same vaccine schedule (0, 1, and 12 months), whereas children were randomized to receive three different schedules (0, 1, and 6; 0, 1, and 2; or 0, 1, and 12 months). After one dose, 141 (96%) of 147 children and 129 (90%) of 143 adults responded with levels of antibody to hepatitis A virus > 20 mIU/mL. After three doses, all participants responded. The geometric mean titer (GMT) 1 month after the third dose was significantly higher in children who received the third dose 12 months after the first dose rather than 2 months after the first dose. While there were differences in the GMT of some blood samples by age, sex, and ethnicity, all participants responded to the vaccine.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Alaska
  • Child, Preschool
  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis Antibodies / blood
  • Hepatovirus / immunology*
  • Humans
  • Indians, North American
  • Sex Factors
  • Vaccines, Inactivated / immunology
  • Viral Hepatitis Vaccines / administration & dosage
  • Viral Hepatitis Vaccines / immunology*

Substances

  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis Antibodies
  • Vaccines, Inactivated
  • Viral Hepatitis Vaccines